



#### FEE PAYMENT FORM (ORDINANCE No. 377/2005, OF APRIL 4) (Read the instructions carefully before filling out)

#### **1. Applicant Identification:**

COMPANY NAME:

TAX NUMBER:

**Tax Office Code:** 

#### 2. Identification of act(s):

Number	Paragraph	Subparagraph	Cost*	<b>Quant</b> Qt1/Qt2	Amount
1. Marketing Authorisation Application	a) National procedure	i) One dosage and one pharmaceutical form	2,915.55€		
		<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	588.23€		
		iii) Each supplementary dosage or pharmaceutical form submitted at a later date	1,759.56€		
		i) One dosage and one pharmaceutical form	1,759.56 €		
	<b>b)</b> National proc. – art. 7, a) and c) of DL 72/91, of February 8:	<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	291.56 €		
		iii) Each supplementary dosage or pharmaceutical form submitted at a later date	588.23€		
		i) One dosage and one pharmaceutical form	7,672.50€		
	c) National proc. – subsequent submittal of an application for Mutual Recognition – where Portugal is a reference member state:	<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	1,759.56 €		
		iii) Each supplementary dosage or pharmaceutical form submitted at a later date	2,046.00€		
	a) Medicine granted a valid effective Marketing Authorisation in Portugal – where Portugal is a reference M.S., except in the conditions set forth in no. 1, c)	i) One dosage and one pharmaceutical form	5,115.00€		
<b>2.</b> Application mutual recognition:		<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	1,314.56€		
		iii) Each supplementary dosage or pharmaceutical form submitted at a later date	1,534.50€		
	b) Medicine granted a Marketing	i) One dosage and one pharmaceutical form	3,069.00€		
	Authorisation issued by another M.S. of the E.U.	<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	613.80€		
		iii) Each supplementary dosage or pharmaceutical form submitted at a later date	767.25 €		
3. Authorisation	a) One dosage and one pharmaceutical form		1,759.56 €		
application for the parallel import of medicines	<b>b)</b> Each supplementary dosage or pharmace	291.56€			
4. Marketing	a) One dosage and one pharmaceutical form		291.56 €		
Authorisation holder transfer application	<b>b)</b> Each supplementary dosage or pharmace	eutical form included in the previous application	102.30 € 797.94 €		
		i) One dosage and one pharmaceutical form ii) Each supplementary dosage and/or	271.10 €		
5. Application to change the terms of a medicine Marketing Authorisation, except	a) Type I variation:	pharmaceutical form included in the previous application			
		iii) When it refers only to changing the name, company name, head office or representation of the Marketing Authorisation holder or the removal of companies participating in the manufacturing, including the release of the batch, the medicine or the active ingredient(s).	184.14 €		
as provided for in nos.		i) One dosage and one pharmaceutical form	1,585.65€		
1 and 2, ii) and iii), and no. 3 b) and d):	<b>b)</b> Type II variation:	ii) Each supplementary dosage and/or pharmaceutical form included in the previous application	511.50 €		
	c) Extensions:	i) Including one dosage and one pharmaceutical form	3,166.19€	I	
		<ul> <li>ii) Each supplementary dosage and/or pharmaceutical form included in the previous application</li> </ul>	368.28 €		
	a) Marketing Authorisation of medicine granted in accordance with the national procedure:	i) One dosage and one pharmaceutical form	1,759.56 €		
		ii) Each supplementary dosage and/or pharmaceutical form included in the previous application	291.58 €		
	<ul> <li>b) Marketing Authorisation granted via the national procedure which was subject to a mutual recognition procedure – Portugal is a reference M.S.</li> <li>c) Mutual recogn. of a Marketing Authorisation granted by the competent authority(ies) of another/other M.S. of the E.U.</li> </ul>	i) One dosage and one pharmaceutical form	2,404.05€		
<b>6.</b> Renewal application:		ii) Each supplementary dosage and/or pharmaceutical form included in the previous	291.56 €		
		application i) One dosage and one pharmaceutical form	1,759.56€		
		ii) Each supplementary dosage and/or	291.56 €		1
		pharmaceutical form included in the previous application	251.50 C		
	medicines – article 59 of DL 72/91, as per the ion to manufacture medicines - article 54 of D	wording given by DL 272/95, of October 23 L 72/91, as per the wording given by DL 272/95, of	588.23 € 588.23 €		
<b>9.</b> For each type of Type	a) Initial batch of up to 10 medicines includ	ing a dosage and a pharmaceutical form	383.63 €		1
I variation, or minor	<ul> <li>a) Initial batch of up to 10 medicines including a dosage and a pharmaceutical form</li> <li>b) More than 10 medicines – each additional batch of 1 to 5 medicines, up to 50</li> </ul>				
variation consisting only of changing the company name, address, head	c) More than 50 medicines – each additional batch of 1 to 5 medicines, up to 120		204.60 € 179.03 €		
office or representation of the manufacturer or of the marketing	d) More than 120 medicines – each additional batch of 1 to 5 medicines				

<b>10.</b> Certificate or document of equivalent value regarding the registration of a medicine – <u>USE APPROPRIATE FORM</u>			
<b>11.</b> The price of performing laboratory tests will be that fixed by the entities that perform them, plus 20% for the			
technical and administrative costs incurred by the National Authority of Medicines and Health Products (INFARMED)			
<b>12.</b> Scientific advice a) Application for simultaneous scientific advice covering the four fields	7,161.00€		
regarding a medicine b) Application for scientific advice covering each of said fields	1,918.13€		
procedure – clinical,			
non-clinical,			
pharmaceutical and			
pharmacokinetic fields.	797.94 €		
13. Regulatory device, per medicine proc.			
14. Arbitration carried out by INFARMED between marketing authorisation holders covering a matter submitted to its			
assessment.			
		-	
		Total	
	·		ed annually
No. of field	s filled out in the a	* updat	ed annually
No. of field Art. 2 – In the event of non-validation of any of the applications referred to in article 1, no. 1 to 9, Infarmed s		* updat mount column	
		* updat mount column	
Art. 2 – In the event of non-validation of any of the applications referred to in article 1, no. 1 to 9, Infarmed s laid down therein, and shall keep the remaining 10 % as payment of administrative expenses.		* updat mount column	
Art. 2 – In the event of non-validation of any of the applications referred to in article 1, no. 1 to 9, Infarmed s		* updat mount column	
Art. 2 – In the event of non-validation of any of the applications referred to in article 1, no. 1 to 9, Infarmed s laid down therein, and shall keep the remaining 10 % as payment of administrative expenses.		* updat mount column	
Art. 2 – In the event of non-validation of any of the applications referred to in article 1, no. 1 to 9, Infarmed s laid down therein, and shall keep the remaining 10 % as payment of administrative expenses.         Applicant's signature and stamp:		* updat mount column	

Act	Medicine name	Pharmaceutical form	Dosage

#### 3. Identification of the medicine(s) for which the act(s) are applied:

# 4. Payment identification:

Cheque number	Bank	<b>Clearing District</b>	Amount		
		Total cheques			
In writing:		Cash			
		Total deposit			
BIN:07810112000000624751 of the account held at Instituto de Gestão de Tesouraria e do Crédito Público, I.P.IBAN:PT5007810112000000624751SWIFT CODE:IGCPPTPL					
The amount of	JTOS DE SAÚDE, I.P. (INI	, payable to AUTOF FARMED, I.P), as paymen	RIDADE NACIONAL DO t for the aforementioned		
Treasury Certification					

Т

## **Filling out instructions**

### 0. General:

Fill out <u>all</u> fields of the "Fee Payment Form" in <u>legible</u> letters. The application will be deemed invalid if not fully filled out or filled out incorrectly.

## 1. Applicant identification:

Always clearly identify the applicant in this field.

## 2. Identification of act/acts:

- The acts shall be indicated in the appropriate line according to the specified description.
- The applicant shall indicate in the respective line the quantity of medicines for which the acts in question are being applied for.
- The payable amount will be determined by multiplying the list price by the quantity of applied medicines.
- In number 5, depending on whether the acts are subject to a 40% reduction or not, the field "Quant. 1" and/or "Quant. 2" shall be filled out, respectively.
- For applications referred to in no. 10, follow the available instructions using the appropriate form.

## 3. Identification of the medicine(s) for which the act/acts are being applied:

- The act shall be identified in the following manner: Number, Paragraph and Subparagraph, e.g.: 6. a) ii).
- For acts applied in accordance with no. 5, indicate the type, paragraph, subparagraph and type of the variation, according to the typification set forth in DL 85/2004, of April 15.
- Medicines shall always be identified by their Name, Pharmaceutical Form and Dosage, whereby this identification information shall be applicable to ONE medicine paragraphs 7, 8, 9, 10, 12.
- Any change either to the dosage or pharmaceutical form is a new medicine.
- However, there are paragraphs where the submittal of supplementary dosages and/or pharmaceutical forms of the same medicine, is accepted a lower cost– paragraphs 1, 2, 3, 4, 5, 6.

#### 4. Payment identification:

This field shall be filled out with the payment means / form.

#### 5. Submitting the "Fee Payment Form" for payments made by bank transfer

The "Fee Payment Form", along with the respective proof of payment, shall be submitted in duplicate. The original shall be included in the dossier to be submitted. The duplicate shall be forwarded to Infarmed's Financial and Property Directorate.